Accelerated metabolism of voriconazole and its partial reversal by cimetidine

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 4, 2009, Pages 1712-1714

  Moriyama, Brad ^a   Elinoff, Jason ^b   Danner, Robert L ^b   Gea Banacloche, Juan ^c   Pennick, Gennethel ^d   Rinaldi, Michael G ^d   Walsh, Thomas J ^c  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b Critical Care Medicine Department   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; BETA CYCLODEXTRIN SULFOBUTYL ETHER; CIMETIDINE; ECHINOCANDIN; VORICONAZOLE;

ADULT; ARTICLE; ASPERGILLUS TERREUS; ASPERGILLUS USTUS; CASE REPORT; CONTINUOUS HEMODIAFILTRATION; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENCY; HEMOPTYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LUNG ASPERGILLOSIS; LUNG LAVAGE; LUNG LOBECTOMY; MALE; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL;

ANTIFUNGAL AGENTS; CIMETIDINE; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; HEMOFILTRATION; HUMANS; MALE; MIDDLE AGED; PYRIMIDINES; TRIAZOLES;

EID: 65649131962     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01221-08     Document Type: Article

References (19)

1. Aitken, A. E., T. A. Richardson, and E. T. Morgan. 2006. Regulation of drug-metabolizing enzymes and transporters in inflammation. Annu. Rev. Pharmacol. Toxicol. 46:123-149. (Pubitemid 43271186)
2. Andes, D., A. Pascual, and O. Marchetti. 2009. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob. Agents Chemother. 53:24-34.
3. Blume, H., F. Donath, A. Warnke, and B. S. Schug. 2006. Pharmacokinetic drug interaction profiles of proton pump inhibitors. Drug Saf. 29:769-784. (Pubitemid 44352242)
4. Bruggemann, R. J. M., J. P. Donnelly, R. E. Aarnoutse, A. Warns, N. M. A. Biyievens, J. W. Mouton, P. E. Verwetj, and D. M. Burger. 2008. Therapeutic drug monitoring of voriconazole. Ther. Drug Monit. 30:403-411. (Pubitemid 46001919)
5. Czock, D., F. Keller, F. M. Rasche, and U. Haussler. 2005. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin. Pharmacokinet. 44:61-98. (Pubitemid 40096038)
6. Fuhrmann, V., P. Schenk, W. Jaeger, M. Miksits, N. Kneidinger, J. Warszawska, U. Holzinger, R. Kitzberger, and F. Thalhammer. 2007. Pharmacokinetics of voriconazole during continuous venovenous haemodiafiltration. J. Antimicrob. Chemother. 60:1085-1090. (Pubitemid 47617758)
7. Iber, H., M. B. Sewer, T. B. Barclay, S. R. Mitchell, T. Li, and E. T. Morgan. 1999. Modulation of drug metabolism in infectious and inflammatory diseases. Drug Metab. Rev. 31:29-41. (Pubitemid 29106650)
8. Luo, G., M. Cunningham, S. Kim, T. Burn, J. Lin, M. Sinz, G. Hamilton, C. Rizzo, S. Jolley, D. Gilbert, A. Downey, D. Mudra, R. Graham, K. Carroll, J. Xie, A. Madan, A. Parkinson, D. Christ, B. Selling, E. LeCluyse, and L. S. Gan. 2002. CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab. Dispos. 30:795-804. (Pubitemid 34671092)
9. Luo, G., T. Guenthner, L. S. Gan, and W. G. Humphreys. 2004. CYP3A4 induction by xenobiotics: biochemistry, experimental methods and impact on drug discovery and development. Curr. Drug Metab. 5:483-505. (Pubitemid 39534494)
10. Moore, L. B., D. J. Parks, S. A. Jones, R. K. Bledsoe, T. G. Consler, J. B. Stimmet, B. Goodwin, C. Liddle, S. G. Blanchard, T. M. Willson, J. L. Collins, and S. A. Kliewer. 2000. Orphan nuclear receptors constitutive androstane receptor and pregnane X receptor share xenobiotic and steroid ligands. J. Biol. Chem. 275:15122-15127. (Pubitemid 30337234)
11. Morgan, E. T., K. B. Goralski, M. Piquette-Miller, K. W. Renton, G. R. Robertson, M. R. Chaluvadi, K. A. Charles, S. J. Clarke, M. Kacevska, C. Liddle, T. A. Richardson, R. Sharma, and C. J. Sinai. 2008. Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer. Drug Metab. Dispos. 36:205-216.
12. Mulanovich, V., R. E. Lewis, I. I. Raad, and D. P. Kontoyiannis. 2007. Random plasma concentrations of voriconazole decline over time. J. Infect. 55:el29-ell30. (Pubitemid 47611512)
13. Pennick, G. J., M. Clark, D. A. Sutton, and M. G. Rinaldi. 2003. Development and validation of a high-performance liquid chromatography assay for voriconazole. Antimicrob. Agents Chemother. 47:2348-2350. (Pubitemid 36753600)
14. Pichard, L., I. Fabre, M. Daujat, J. Domergue, H. Joyeux, and P. Maurel. 1992. Effect of corticosteroids on the expression of cytochromes F450 and on cyclosporin A oxidase activity in primary cultures of human hepatocytes. Mol. Pharmacol. 41:1047-1055. (Pubitemid 23026103)
15. Purkins, L., N. Wood, D. Kleinermans, and D. Nichols. 2003. Histamine H2-receptor antagonists have no clinically significant effect on the steady-state pharmacokinetics of voriconazole. Br. J. Clin. Pharmacol. 56(Suppl. l):51-55. (Pubitemid 37491734)
16. Renton, K. W. 2005. Regulation of drug metabolism and disposition during inflammation and infection. Expert. Opin. Drug Metab. Toxicol. 1:629-640.
17. Robatel, C, M. Rusca, C. Padoin, O. Marchetti, L. Liaudet, and T. Buclin. 2004. Disposition of voriconazole during continuous veno-venous haemodiaflltration (CWHDF) in a single patient. J. Antimicrob. Chemother. 54: 269-270. (Pubitemid 39029007)
18. Roffey, S. J., S. Cole, P. Comby, D. Gibson, S. G. Jezequel, A. N. R. Nedderman, D. A. Smith, D. K. Walker, and N. Wood. 2003. The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human. Drug Metab. Dispos. 31:731-741. (Pubitemid 36617661)
19. Seidegard, J., M. Simonsson, and S. Edsbacker. 2000. Effect of an oral contraceptive on the plasma levels of budesonide and prednisolone and the influence on plasma Cortisol. Clin. Pharmacol. Ther. 67:373-381. (Pubitemid 30246814)